Skip to main content
Premium Trial:

Request an Annual Quote

Waters Reduces Q3 Revenue Growth to 3 Percent; Cites Declining US Sales

NEW YORK, Oct. 14 (GenomeWeb News) - Waters today said that "slower than expected" sales growth has forced it to expect lower-than-expected third-quarter sales and earnings per diluted share.


In its second-quarter conference call July 26, Waters said it anticipated sales to grow 8 percent in the third quarter year over year. The company now expects growth to be around 3 percent year over year.


Waters generated $264.8 million in revenues during the third quarter 2004. Based on the company's renewed projections, third-quarter 2005 receipts are now expected to be around $272.7 million.


Third-quarter earnings per share, which Waters originally said would be $.47, are now projected at approximately $.43, excluding a $24-million tax provision to be recorded in the third quarter related to a dividend distribution.

Organic sales growth in the quarter was also 3 percent as foreign currency translation "had little incremental effect" on third-quarter revenue, Waters said.


Geographically, sales declined in the United States, where instrument sales to large pharmaceutical accounts were "less than expected" due to delays associated with both the evaluation of new products and the release of capital budgets, Waters said.


However, strong sales growth in Asiawere "largely in line" with expectations.


Sales of liquid-chromatography products grew "moderately" in the third quarter 2005 compared with the prior year, while mass spectrometry sales "modestly" declined. Thermal analysis instrument sales grew in the quarter at a rate that was higher than Water's overall growth rate, the company said.

Global sales to life-science companies were "roughly flat" in the quarter, while a "relatively strong" performance of Waters' industrial business was largely offset by a decline in sales to governmental and academic institutions, the company said.
"At this time, the company anticipates a continuation of the challenging business conditions experienced in the third quarter, with comparable sales growth before currency impacts, and is evaluating opportunities to control operating expenses," Waters said in a statement.


Waters will release its full third-quarter earnings on Oct. 25.

The Scan

Researchers Compare WGS, Exome Sequencing-Based Mendelian Disease Diagnosis

Investigators find a diagnostic edge for whole-genome sequencing, while highlighting the cost advantages and improving diagnostic rate of exome sequencing in EJHG.

Researchers Retrace Key Mutations in Reassorted H1N1 Swine Flu Virus With Avian-Like Features

Mutations in the acidic polymerase-coding gene boost the pathogenicity and transmissibility of Eurasian avian-like H1N1 swine influenza viruses, a PNAS paper finds.

Genome Sequences Reveal Evolutionary History of South America's Canids

An analysis in PNAS of South American canid species' genomes offers a look at their evolutionary history, as well as their relationships and adaptations.

Lung Cancer Response to Checkpoint Inhibitors Reflected in Circulating Tumor DNA

In non-small cell lung cancer patients, researchers find in JCO Precision Oncology that survival benefits after immune checkpoint blockade coincide with a dip in ctDNA levels.